Alternative Name: MENT Transdermal Gel

Description: MENT is a synthetic androgen that resembles testosterone. MENT binds to androgen receptors with greater binding affinity than testosterone and dihydrotestosterone, the two active endogenous androgens. The higher binding affinity results in higher bioactivity so that the total dose can be reduced compared to the dose of testosterone required for daily use.

Product Details

User: Male

Hormonal: Yes

Delivery Method: Transdermal

Duration Type: Short-acting

  • daily

Active Pharmaceutical Ingredient (API):
  • 7alpha-Methyl-19-Nortestosterone

Inactive material: ethanol; other absorption enhancers

Multipurpose Preventive Technology (MPT): No

Status Details

Developer: Population Council

Project Phase: Pre-Clinical and Clinical Development

Development Stage: Phase I

Began discovery in: 1995

Active Development: No

Status Details:
  • Early studies indicated that MENT gel suppressed steroid sex hormones over a seven-day treatment period, and that the effect was reversible when treatment ended.
  • MENT was licensed to Schering AG, Germany for replacement therapy in 2001. After the acquisition by Bayer, the company decided to close the program.

Additional Information

  • See also entry on MENT Implant.

Vertical Tabs